Human Clinical Trials Of HIV/AIDS Vaccine Making Steady Progress
The first and only preventative HIV vaccine based on a genetically modified killed whole-virus has been making steady progress in Phase I Clinical Trials in the United States and the interim results are being analyzed in preparation for the next steps. Developed by Dr. Chil-Yong Kang and his team at Western University's Schulich School of Medicine & Dentistry, with the support of Sumagen Canada, the vaccine (SAV001-H) holds tremendous promise for success in the final phases of clinical testing now that the first hurdle has been accomplished...
aids
canada
chil-yong
dentistry
hiv
kang
medicine
phase
preparation
sav
school
schulich
states
sumagen
united
university
western
Sorry, we didn't find any more articles related to the one you selected.
Use the oxo and xox buttons to remove the tags that seem least relevant to you.
After removing a tag, you can either add more tags or use the the search function to refine your search.
You can start over with a new tag selection by choosing a tag from the tag clouds on the left or by using the search function.
Or jump to the list of our fresh
articles.